Table 4. Baseline characteristics of... | American Society of Hematology

Table 4.

Baseline characteristics of prior therapies and study outcomes

Patient ID	Baseline characteristics				Study outcomes
Patient ID	Most recent prior regimen	PI refractory yes/no	Pomalidomide refractory yes/no	Lenlidomide refractory yes/no; dose	Duration on lenalidomide 25 mg (mo)	Lenalidomide dose at time of PD	Best response	PFS
1	Filanesib/bortezomib/dex	Yes	No	No/25 mg*	1	10	PR	4
2	Bortezomib + dexamethasone	Yes	No	No/25 mg*	2	15	PR	31
3	Melphalan ASCT	No	No	No	8	25	CR	20
4	Bortezomib/lenalidomide/dex	Yes	No	No/25 mg*	7	25	MR	7
5	Melphalan ASCT	No	No	No/25 mg	7	25	MR	7
6	Bortezomib + DCEP	Yes	Yes	Yes/5 mg	1	15	MR	1
7	Bortezomib/lenalidomide/dex	Yes	No	Yes/10 mg	2	15	MR	6
8	Bortezomib/lenalidomide/dex	No	No	Yes/10 mg	6	25	MR	7
9	Lenalidomide	No	No	Yes/10 mg	4	25	PR	11
10	Melphalan ASCT	No	No	Yes/10 mg	3	15	PR	26†
11	DCEP	Yes	Yes	Yes/10 mg	8	25	SD	8
12	Lenalidomide dexamethasone	No	No	Yes/10 mg	2	10	VGPR	15
13	Lenalidomide	No	No	Yes/10 mg	12	25	VGPR	14
14	Lenalidomide	No	No	Yes/15 mg	4	25	MR	4
15	Lenalidomide dexamethasone	Yes	Yes	Yes/15 mg	2	15	MR	4
16	Lenalidomide dexamethasone	Yes	No	Yes/15 mg	6	25	SD	6
17	Lenalidomide	No	No	Yes/15 mg	1	10	SD	31
18	Melphalan ASCT	No	No	Yes/15 mg	1	25	SD	1
19	PomCyDex	Yes	Yes	Yes/25 mg	1	10	MR	1
20	Lenalidomide dexamethasone	No	No	Yes/25 mg	4	25	MR	5
21	Carfilzomib + dexamethasone	Yes	Yes	Yes/25 mg	2	25	PD	2
22	PomCyDex	Yes	Yes	Yes/25 mg	30	25	PR	30†
23	Carfilzomib	Yes	Yes	Yes/25 mg	8	15	VGPR	10
24	Bortezomib	Yes	Yes	Yes/25 mg	4	10	CR	19
25	Bortezomib + dexamethasone	Yes	No	Yes/25 mg	19	25	VGPR	19
26	Melphalan ASCT	Yes	No	Yes/unknown	1	25	SD	1
27	Borteozmib + bendamustine	Yes	Yes	Yes/unknown	4	25	SD	5

Patient ID	Baseline characteristics				Study outcomes
Patient ID	Most recent prior regimen	PI refractory yes/no	Pomalidomide refractory yes/no	Lenlidomide refractory yes/no; dose	Duration on lenalidomide 25 mg (mo)	Lenalidomide dose at time of PD	Best response	PFS
1	Filanesib/bortezomib/dex	Yes	No	No/25 mg*	1	10	PR	4
2	Bortezomib + dexamethasone	Yes	No	No/25 mg*	2	15	PR	31
3	Melphalan ASCT	No	No	No	8	25	CR	20
4	Bortezomib/lenalidomide/dex	Yes	No	No/25 mg*	7	25	MR	7
5	Melphalan ASCT	No	No	No/25 mg	7	25	MR	7
6	Bortezomib + DCEP	Yes	Yes	Yes/5 mg	1	15	MR	1
7	Bortezomib/lenalidomide/dex	Yes	No	Yes/10 mg	2	15	MR	6
8	Bortezomib/lenalidomide/dex	No	No	Yes/10 mg	6	25	MR	7
9	Lenalidomide	No	No	Yes/10 mg	4	25	PR	11
10	Melphalan ASCT	No	No	Yes/10 mg	3	15	PR	26†
11	DCEP	Yes	Yes	Yes/10 mg	8	25	SD	8
12	Lenalidomide dexamethasone	No	No	Yes/10 mg	2	10	VGPR	15
13	Lenalidomide	No	No	Yes/10 mg	12	25	VGPR	14
14	Lenalidomide	No	No	Yes/15 mg	4	25	MR	4
15	Lenalidomide dexamethasone	Yes	Yes	Yes/15 mg	2	15	MR	4
16	Lenalidomide dexamethasone	Yes	No	Yes/15 mg	6	25	SD	6
17	Lenalidomide	No	No	Yes/15 mg	1	10	SD	31
18	Melphalan ASCT	No	No	Yes/15 mg	1	25	SD	1
19	PomCyDex	Yes	Yes	Yes/25 mg	1	10	MR	1
20	Lenalidomide dexamethasone	No	No	Yes/25 mg	4	25	MR	5
21	Carfilzomib + dexamethasone	Yes	Yes	Yes/25 mg	2	25	PD	2
22	PomCyDex	Yes	Yes	Yes/25 mg	30	25	PR	30†
23	Carfilzomib	Yes	Yes	Yes/25 mg	8	15	VGPR	10
24	Bortezomib	Yes	Yes	Yes/25 mg	4	10	CR	19
25	Bortezomib + dexamethasone	Yes	No	Yes/25 mg	19	25	VGPR	19
26	Melphalan ASCT	Yes	No	Yes/unknown	1	25	SD	1
27	Borteozmib + bendamustine	Yes	Yes	Yes/unknown	4	25	SD	5

ASCT, autologous stem cell transplant; DCEP, dexamethasone, cyclophosphamide, etoposide, cisplatinum; dex, dexamethasone; ID, identification; PomCyDex, pomalidomide cyclophosphamide dexamethasone.

Less than PR to last lenalidomide-containing regimen.

†

Patients completed study treatment but continued on commercial supply of FRD.

View Large

This Feature Is Available To Subscribers Only